Skip to main content

Prognostic impact of C-reactive protein-albumin ratio for the lethality in castration-resistant prostate cancer

Medical Oncology volume 37, Article number: 9 (2020) Cite this article

Abstract

This study aimed to assess the clinical value of C-reactive protein-albumin ratio (CAR) at the initiation of first-line treatment for castration-resistant prostate cancer (CRPC). We identified 221 CRPC patients treated with either androgen-signaling inhibitors (ASIs: abiraterone and enzalutamide) or docetaxel as the first-line treatment. The value of CAR was evaluated at the initiation of first-line treatment. The optimal cutoff value of CAR for the prediction of lethality was defined by the receiver operating characteristic curve and the Youden Index. The primary endpoints of the study included overall survival (OS) and cancer-specific survival (CSS). The median age was 74 years. The optimal cutoff value of CAR in newly diagnosed CRPC patients was 0.5 (CAR > 0.5: n = 77 and CAR ≤ 0.5: n = 144). The 3-year OS and CSS rate in patients with CAR > 0.5 were significantly lower than those with CAR ≤ 0.5 (OS: 30.9% vs 55.5%, p < 0.001) (CSS: 42.5% vs 65.4%, p < 0.001). A multivariate analysis consistently demonstrated that CAR was an independent predictor for both OS and CSS. When stratified by the first-line treatments, patients with CAR > 0.5 has significantly shorter CSS than those with CAR ≤ 0.5 in abiraterone (median of 23 vs 49 months, p < 0.001) and enzalutamide (median of 23 vs 41 months, p = 0.0016), whereas no difference was observed in patients treated with docetaxel as the first-line treatment (median of 34 and 37 months, p = 0.7708). Despite the limited cohort size and retrospective design, increased CAR seemed to serve as an independent predictor of OS and CSS for patients newly diagnosed with CRPC.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

References

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34.

    Article  Google Scholar 

  2. Mazzu YZ, Armenia J, Chakraborty G, et al. A novel mechanism driving poor-prognosis prostate cancer: overexpression of the DNA repair gene, ribonucleotide reductase small subunit M2 (RRM2). Clin Cancer Res. 2019;25(14):4480–92.

    Article  Google Scholar 

  3. Sun T, Du SY, Armenia J, et al. Expression of lncRNA MIR222HG co-transcribed from the miR-221/222 gene promoter facilitates the development of castration-resistant prostate cancer. Oncogenesis. 2018;7(3):30.

    Article  Google Scholar 

  4. Komura K, Yoshikawa Y, Shimamura T, et al. ATR inhibition controls aggressive prostate tumors deficient in Y-linked histone demethylase KDM5D. J Clin Investig. 2018;128(7):2979–95.

    Article  Google Scholar 

  5. Komura K, Jeong SH, Hinohara K, et al. Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression. Proc Natl Acad Sci USA. 2016;113(22):6259–64.

    CAS  Article  Google Scholar 

  6. Komura K, Sweeney CJ, Inamoto T, Ibuki N, Azuma H, Kantoff PW. Current treatment strategies for advanced prostate cancer. Int J Urol. 2018;25(3):220–31.

    Article  Google Scholar 

  7. Arthur R, Williams R, Garmo H, et al. Serum inflammatory markers in relation to prostate cancer severity and death in the Swedish AMORIS study. Int J Cancer. 2018;142(11):2254–62.

    CAS  Article  Google Scholar 

  8. Yang JR, Xu JY, Chen GC, et al. Post-diagnostic C-reactive protein and albumin predict survival in Chinese patients with non-small cell lung cancer: a prospective cohort study. Sci Rep. 2019;9(1):8143.

    Article  Google Scholar 

  9. Ni XF, Wu J, Ji M, et al. Effect of C-reactive protein/albumin ratio on prognosis in advanced non-small-cell lung cancer. Asia Pac J Clin Oncol. 2018;14(6):402–9.

    Article  Google Scholar 

  10. Zhang F, Ying L, Jin J, et al. The C-reactive protein/albumin ratio predicts long-term outcomes of patients with operable non-small cell lung cancer. Oncotarget. 2017;8(5):8835–42.

    PubMed  Google Scholar 

  11. Miyazaki T, Yamasaki N, Tsuchiya T, et al. Ratio of C-reactive protein to albumin is a prognostic factor for operable non-small-cell lung cancer in elderly patients. Surg Today. 2017;47(7):836–43.

    CAS  Article  Google Scholar 

  12. Koh YW, Lee HW. Prognostic impact of C-reactive protein/albumin ratio on the overall survival of patients with advanced nonsmall cell lung cancers receiving palliative chemotherapy. Medicine (Baltimore). 2017;96(19):e6848.

    CAS  Article  Google Scholar 

  13. Konishi S, Hatakeyama S, Tanaka T, et al. C-reactive protein/albumin ratio is a predictive factor for prognosis in patients with metastatic renal cell carcinoma. Int J Urol. 2019;26(10):992–8.

    CAS  Article  Google Scholar 

  14. Tsujino T, Komura K, Hashimoto T, et al. C-reactive protein-albumin ratio as a prognostic factor in renal cell carcinoma—a data from multi-institutional study in Japan. Urol Oncol. 2019;14(10):e0224266.

    Google Scholar 

  15. Gao J, Agizamhan S, Zhao X, et al. Preoperative C-reactive protein/albumin ratio predicts outcome of surgical papillary renal cell carcinoma. Future Oncol. 2019;15(13):1459–68.

    Article  Google Scholar 

  16. Guo S, He X, Chen Q, et al. The C-reactive protein/albumin ratio, a validated prognostic score, predicts outcome of surgical renal cell carcinoma patients. BMC Cancer. 2017;17(1):171.

    Article  Google Scholar 

  17. Chen Z, Shao Y, Fan M, et al. Prognostic significance of preoperative C-reactive protein: albumin ratio in patients with clear cell renal cell carcinoma. Int J Clin Exp Pathol. 2015;8(11):14893–900.

    CAS  PubMed  PubMed Central  Google Scholar 

  18. Guo Y, Cai K, Mao S, et al. Preoperative C-reactive protein/albumin ratio is a significant predictor of survival in bladder cancer patients after radical cystectomy: a retrospective study. Cancer Manag Res. 2018;10:4789–804.

    CAS  Article  Google Scholar 

  19. Kunizaki M, Tominaga T, Wakata K, et al. Clinical significance of the C-reactive protein-to-albumin ratio for the prognosis of patients with esophageal squamous cell carcinoma. Mol Clin Oncol. 2018;8(2):370–4.

    CAS  PubMed  Google Scholar 

  20. Yu X, Wen Y, Lin Y, et al. The value of preoperative glasgow prognostic score and the C-reactive protein to albumin ratio as prognostic factors for long-term survival in pathological T1N0 esophageal squamous cell carcinoma. J Cancer. 2018;9(5):807–15.

    Article  Google Scholar 

  21. Wu MT, He SY, Chen SL, et al. Clinical and prognostic implications of pretreatment albumin to C-reactive protein ratio in patients with hepatocellular carcinoma. BMC Cancer. 2019;19(1):538.

    Article  Google Scholar 

  22. Shimizu T, Ishizuka M, Suzuki T, et al. The value of the C-reactive protein-to-albumin ratio is useful for predicting survival of patients with child-pugh class a undergoing liver resection for hepatocellular carcinoma. World J Surg. 2018;42(7):2218–26.

    Article  Google Scholar 

  23. Kinoshita A, Onoda H, Imai N, et al. The C-reactive protein/albumin ratio, a novel inflammation-based prognostic score, predicts outcomes in patients with hepatocellular carcinoma. Ann Surg Oncol. 2015;22(3):803–10.

    Article  Google Scholar 

  24. Kuboki A, Kanaya H, Nakayama T, et al. Prognostic value of C-reactive protein/albumin ratio for patients with hypopharyngeal and laryngeal cancer undergoing invasive surgery involving laryngectomy. Head Neck. 2019;41(5):1342–50.

    Article  Google Scholar 

  25. World Medical A. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191–4.

    Article  Google Scholar 

  26. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26(7):1148–59.

    Article  Google Scholar 

  27. Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3(1):32–5.

    CAS  Article  Google Scholar 

  28. Unal I. Defining an optimal cut-point value in ROC analysis: an alternative approach. Comput Math Methods Med. 2017;2017:3762651.

    Article  Google Scholar 

  29. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15(4):361–87.

    Article  Google Scholar 

  30. Komura K, Hashimoto T, Tsujino T, et al. The CANLPH score, an integrative model of systemic inflammation and nutrition status (SINS), predicts clinical outcomes after surgery in renal cell carcinoma: data from a multicenter cohort in Japan. Ann Surg Oncol. 2019;26(9):2994–3004.

    Article  Google Scholar 

  31. Okamoto T, Hatakeyama S, Narita S, et al. Impact of nutritional status on the prognosis of patients with metastatic hormone-naive prostate cancer: a multicenter retrospective cohort study in Japan. World J Urol. 2019;37(9):1827–35.

    CAS  Article  Google Scholar 

  32. Beer TM, Tangen CM, Bland LB, et al. The prognostic value of hemoglobin change after initiating androgen-deprivation therapy for newly diagnosed metastatic prostate cancer: a multivariate analysis of Southwest Oncology Group Study 8894. Cancer. 2006;107(3):489–96.

    CAS  Article  Google Scholar 

  33. Shafique K, Proctor MJ, McMillan DC, et al. The modified Glasgow prognostic score in prostate cancer: results from a retrospective clinical series of 744 patients. BMC Cancer. 2013;13:292.

    Article  Google Scholar 

  34. Leibowitz-Amit R, Templeton AJ, Omlin A, et al. Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer. Ann Oncol. 2014;25(3):657–62.

    CAS  Article  Google Scholar 

  35. Liu ZQ, Chu L, Fang JM, et al. Prognostic role of C-reactive protein in prostate cancer: a systematic review and meta-analysis. Asian J Androl. 2014;16(3):467–71.

    Article  Google Scholar 

  36. Richter E, Connelly RR, Moul JW. The role of pretreatment serum albumin to predict pathological stage and recurrence among radical prostatectomy cases. Prostate Cancer Prostatic Dis. 2000;3(3):186–90.

    CAS  Article  Google Scholar 

  37. Mori K, Kimura T, Onuma H, et al. Lactate dehydrogenase predicts combined progression-free survival after sequential therapy with abiraterone and enzalutamide for patients with castration-resistant prostate cancer. Prostate. 2017;77(10):1144–50.

    CAS  Article  Google Scholar 

  38. Gravis G, Boher JM, Fizazi K, et al. Prognostic factors for survival in noncastrate metastatic prostate cancer: validation of the glass model and development of a novel simplified prognostic model. Eur Urol. 2015;68(2):196–204.

    Article  Google Scholar 

  39. Qu F, Xie W, Nakabayashi M, et al. Association of AR-V7 and prostate-specific antigen RNA levels in blood with efficacy of abiraterone acetate and enzalutamide treatment in men with prostate cancer. Clin Cancer Res. 2017;23(3):726–34.

    CAS  Article  Google Scholar 

Download references

Funding

This work was partially supported by Grant-in-Aid No. 19K18624 (Japan Society for the Promotion of Science: JSPS), the Uehara Memorial Foundation, the NOVARTIS Foundation (Japan) for the Promotion of Science, Japan Research Foundation for Clinical Pharmacology, Yamaguchi Endocrine Disease Research Foundation, and the Takeda Science Foundation 2018 in Japan.

Author information

Affiliations

  1. Department of Urology, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki City, Osaka, 569-8686, Japan

    Taizo Uchimoto, Kazumasa Komura, Yuya Fujiwara, Kenkichi Saito, Naoki Tanda, Takeshi Tsutsumi, Yuki Yoshikawa, Hirofumi Uehara, Hajime Hirano, Hayahito Nomi, Naokazu Ibuki, Teruo Inamoto & Haruhito Azuma

  2. Department of Urology, Saiseikai-Nakatsu Hospital, 2-10-39 Shibata, Kita-ku, Osaka City, Osaka, 530-0012, Japan

    Taizo Uchimoto

  3. Translational Research Program, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki City, Osaka, 569-8686, Japan

    Kazumasa Komura, Kohei Taniguchi & Tomohito Tanaka

  4. Department of Urology, Osaka Medical College Mishima-Minami Hospital, 8-1 Tamagawa-shinmachi, Takatsuki City, Osaka, 569-0856, Japan

    Tomohisa Matsunaga & Koichiro Minami

  5. Department of Urology, Aijinkai-Takatsuki Hospital, 1-3-13 Kosobecho, Takatsuki City, Osaka, 569-1192, Japan

    Atsushi Ichihashi

  6. Division of Urology, Department of Surgery, Brigham and Women’s Hospital, 75 Francis St, Boston, MA, 02115, USA

    Takuya Tsujino & Tomoaki Takai

  7. Department of Urology, Hirakata Municipal Hospital, 2-14-1 Kinyahonmachi, Hirakata City, Osaka, 573-1013, Japan

    Yudai Nishimoto

  8. Department of Urology, Fujita-Health University School of Medicine, 1-98 Dengakugakubo, Kutsukake, Toyoake City, Nagoya, Aichi, 470-1192, Japan

    Kiyoshi Takahara

Authors
  1. Taizo Uchimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kazumasa Komura
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yuya Fujiwara
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kenkichi Saito
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Naoki Tanda
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tomohisa Matsunaga
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Atsushi Ichihashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Takeshi Tsutsumi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Takuya Tsujino
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Yuki Yoshikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Yudai Nishimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Tomoaki Takai
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Koichiro Minami
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Kohei Taniguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Tomohito Tanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Hirofumi Uehara
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Hajime Hirano
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Hayahito Nomi
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Naokazu Ibuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Kiyoshi Takahara
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. Teruo Inamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. Haruhito Azuma
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kazumasa Komura.

Ethics declarations

Conflict of interest

All authors declared that they have no conflict of interest.

Ethical approval

The study design was approved in the institutional review board of Osaka Medical College (IRB Approval Number: RIN-750-2571).

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Uchimoto, T., Komura, K., Fujiwara, Y. et al. Prognostic impact of C-reactive protein-albumin ratio for the lethality in castration-resistant prostate cancer. Med Oncol 37, 9 (2020). https://doi.org/10.1007/s12032-019-1332-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-019-1332-7

Keywords

  • Castration-resistant prostate cancer
  • Abiraterone
  • Enzalutamide
  • Docetaxcel
  • C-reactive protein-albumin ratio